163 related articles for article (PubMed ID: 27789848)
1. Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
Lanzafame M; Lattuada E; Nicolè S; Rigo F; Cucchetto G; Concia E; Vento S
Int J STD AIDS; 2017 Jun; 28(7):726-728. PubMed ID: 27789848
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
[TBL] [Abstract][Full Text] [Related]
3. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;
J Antimicrob Chemother; 2017 Apr; 72(4):1163-1171. PubMed ID: 28093483
[TBL] [Abstract][Full Text] [Related]
4. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Castagna A; Rusconi S; Gulminetti R; Bonora S; Mazzola G; Quiros-Roldan ME; De Socio GV; Ladisa N; Carosella S; Cattelan A; Di Giambenedetto S; Mena M; Poli A; Galli L; Riva A;
AIDS; 2019 Jun; 33(7):1256-1260. PubMed ID: 30870194
[TBL] [Abstract][Full Text] [Related]
5. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
6. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
[TBL] [Abstract][Full Text] [Related]
8. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
Joly V; Burdet C; Landman R; Vigan M; Charpentier C; Katlama C; Cabié A; Benalycherif A; Peytavin G; Yeni P; Mentre F; Argoud AL; Amri I; Descamps D; Yazdanpanah Y;
J Antimicrob Chemother; 2019 Mar; 74(3):739-745. PubMed ID: 30476165
[TBL] [Abstract][Full Text] [Related]
10. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
11. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
12. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
Vizcarra P; Fontecha M; Monsalvo M; Vivancos MJ; Rojo A; Casado JL
Antivir Ther; 2019; 24(6):467-471. PubMed ID: 31172977
[TBL] [Abstract][Full Text] [Related]
14. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
16. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
19. Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
Lombardi F; Belmonti S; Fabbiani M; Borghetti A; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2016 Dec; 71(12):3621-3622. PubMed ID: 27494930
[No Abstract] [Full Text] [Related]
20. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
